Proving the safety and efficacy of a drug, device, or therapy is
the most critical objective for life sciences organizations. The
process of bringing a breakthrough product to market involves many
parties, including patients, doctors, government, corporations, and
clinical research institutions. Since the number of resources
involved in the development of a product has increased over the
years, analyzing the data collected has become very complicated. To
effectively combat the complexity of safety and risk management,
companies large and small are investing heavily in robust clinical
safety applications.
BioPharm Systems' safety and pharmacovigilance practice offers
consulting, implementation, integration, upgrade, and migration
services for the most widely used and highly sought after
safety, risk, and signal management systems in the world,
which include Oracle's:
Our expertise in safety and pharmacovigilance allows
organizations to:
- Meet strict global compliance guidelines
- Manage data from multiple sources
- Decrease case processing time
- Reduce time-to-market
- Minimize overall costs
If you are interested in migrating to Argus Safety from a legacy
pharmacovigilance system, please visit Accel-Migrate to learn more about
our comprehensive solution.
>>
Register for the upcoming webinar: Using
Oracle's Empirica Topics to Document Your Signal Management Process
>> Watch the
webinar: How to Migrate Drug Safety and
Pharmacovigilance Data Cost-Effectively and with Minimum
Risk
>>
Watch the webinar: Business and Operational Risks in Clinical
and Safety: Applying Appropriate Technology and Approaches to
Mitigate Risk
>>
Watch the webinar: Oracle Argus Safety and Oracle Argus Safety
Japan: A Unified Solution that Facilitates Compliant Reporting to a
Japanese Regulator
>>
Watch the webinar: Argus Safety - Planning for the New
Individual Case Safety Report (ICSR) International Standard and
Upcoming ICSR Reporting Changes
>> Schedule
a live demonstration of Accel-Safety/Argus Safety 7.0 or Adverse
Event Reporting System
